Impact of denosumab on cardiovascular calcification in patients with secondary hyperparathyroidism undergoing dialysis: a pilot study
Sign Up to like & getrecommendations! Published in 2020 at "Osteoporosis International"
DOI: 10.1007/s00198-020-05391-3
Abstract: The receptor activator of nuclear factor-kappa B ligand (RANKL)/RANK/osteoprotegerin system is dysregulated in hyperparathyroid bone diseases. The introduction of denosumab preceding elective surgery as an alternative option when surgery is not possible immediately. The effects… read more here.
Keywords: patients secondary; calcification patients; group; denosumab ... See more keywords